Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 3 » Issue 2

The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic

Authors Jeffrey R Strawn, Thomas D Geracioti Jr

Published Date June 2007 Volume 2007:3(2) Pages 237—243

DOI

Published 8 June 2007

Jeffrey R Strawn1,2,3, Thomas D Geracioti Jr1,2,3

1Department of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, OH, USA; 2Research and 3Psychiatry Services, Cincinnati Veterans Affairs Medical Center Cincinnati, OH, USA

Abstract: A constellation of pharmacologic treatments for generalized anxiety disorder (GAD) have been developed over the past five decades, although each has a number of potential drawbacks in clinical practice. This review addresses one potentially new pharmacologic treatment for generalized anxiety disorder, the gamma-aminobutyric acid analogue pregabalin. We review the mechanism of action, and pharmacokinetic and pharmacodynamic properties of pregabalin as well as the results of 5 double-blind, placebo-controlled trials of pregabalin in the treatment of generalized anxiety disorder (GAD). Based entirely on data from these industry-sponsored (Pfizer), multi-site clinical trials in patients with GAD, pregabalin appears to be generally well tolerated and has rapid onset of action (approximately 1 week), comparable efficacy to benzodiazepines and lower discontinuation rates compared with other pharmacologic treatments. Thus in GAD, a disorder that is often suboptimally responsive to traditional psychotherapeutic and psychopharmacologic interventions – secondary to poor efficacy, tolerability, and/or side-effects – pregabalin may have a primary role in GAD patients, especially in those with certain psychiatric comorbidities or individuals who are on multi-drug regimens for medical comorbidities.

Keywords: GAD, pregabalin, panic attack, anxiety disorders, antidepressant, anxiolytic

Download Article [PDF] 

Readers of this article also read:

Binding of plasma proteins to titanium dioxide nanotubes with different diameters

Kulkarni M, Flašker A, Lokar M, Mrak-Poljšak K, Mazare A, Artenjak A, Čučnik S, Kralj S, Velikonja A, Schmuki P, Kralj-Iglič V, Sodin-Semrl S, Iglič A

International Journal of Nanomedicine 2015, 10:1359-1373

Published Date: 18 February 2015

A cross-sectional study on perception of stigma by Chinese schizophrenia patients [Expression of concern]

Ren ZB, Wang HQ, Feng B, Gu CY, Ma YC, Chen H, Li BL, Liu LY

Neuropsychiatric Disease and Treatment 2014, 10:1333-1334

Published Date: 18 July 2014

MRI-based identification of undifferentiated cells: looking at the two faces of Janus

Tomuleasa C, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A

International Journal of Nanomedicine 2014, 9:865-866

Published Date: 11 February 2014

Are calcifying microvesicles another analogous substructure of calcifying nanoparticles?

Atughonu TC, Arja SB, Shiekh FA

International Journal of Nanomedicine 2013, 8:4673-4676

Published Date: 5 December 2013

BAK additive influence on results

Shah RD, Lemon TI, Yarrow-Jenkins A

Clinical Ophthalmology 2013, 7:1081-1082

Published Date: 6 June 2013

Retraction

Cárdenas WH, Mamani JB, Sibov TT, Caous CA, Amaro E Jr, Gamarra LF

International Journal of Nanomedicine 2012, 7:5107-5108

Published Date: 21 September 2012

Grafting of a novel gold(III) complex on nanoporous MCM-41 and evaluation of its toxicity in Saccharomyces cerevisiae

Fazaeli Y, Amini MM, Ashourion H, Heydari H, Majdabadi A, Jalilian AR, Abolmaali S

International Journal of Nanomedicine 2011, 6:3251-3257

Published Date: 12 December 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010